InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,442.00
(
2.14%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,872.61
(
-0.03%
)
Post# of 251704
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119566
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 171477

Wednesday, 12/18/2013 4:32:49 PM

Wednesday, December 18, 2013 4:32:49 PM

Post# of 251704
Based on the ION-2 data, GILD’s GT1 regimen will include ribavirin for treatment-experienced patients, which means the regimen will effectively be BID, not qD. For treatment-naïve patients (possibly excluding cirrhotics), GILD will have a bona fide qD regimen.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up